A systematic review of preclinical animal studies on fenofibrate’s potential role in type 1 diabetic micro-vascular complications
DOI:
https://doi.org/10.1590/s2175-97902022e21332Keywords:
Diabetic cardiomyopathy, Diabetic retinopathy, Fenofibrate, Sphingolipid, Type 1 diabetic microvascular complications, Type 1 Diabetes mellitusAbstract
Fenofibrate is a peroxisome-proliferator-activator α agonist and it is a widely used drug for hyperlipidemia since its approval in 2004. So, in this review we are focusing on the effect of fenofibric acid’s mechanism to alleviate type 1 diabetic micro vascular complications like diabetic retinopathy, diabetic cardiomyopathy in animal models, since the drug is safe, efficacious and more economical when compared with the currently available treatment strategies for juvenile diabetic complications and also a profound observation is needed due to the rarity of research in these therapeutic areas. Important preclinical animal studies published from January 2001 to June 2020 were recognised from databases like PubMed and Cochrane central register of controlled trials. Reviewers screened the articles based on the selection criteria and risk of bias was determined using Systematic Review Centre for Laboratory animal Experimentation risk of bias tool for animal studies. Our literature search yielded a total of 5 studies and after pooling up the data from the 5 preclinical studies, we found that Fenofibrate have the efficacy to prevent type 1 diabetic complications, chiefly diabetic retinopathy and those mechanisms are dependent on peroxisome-proliferator-activator and fibroblast growth factor-21 pathways. Fenofibrate is a well safe and moreover, cost effective medication in preventing type 1 diabetic micro vascular complications especially diabetic retinopathy and also in maintaining the glucose homeostasis in apart from its anti-dyslipidemic effect.
Downloads
References
Balfour JA, McTavish D, Heel RC. Fenofibrate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia. Drugs. 1990;40(2):260-290.
Buschard K, Holm LJ, Feldt-Rasmussen U. Insulin independence in newly diagnosed Type 1 Diabetes patient following fenofibrate treatment. Case Rep Med. 2020;2020:11-3.
Buse JB, Friedewald WT, Bigger JT, Byington RP, Cushman WC, Genuth S, et al. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: Design and methods. Am J Cardiol. 2007;99(12A):21i-33i.
Centers for Disease Control and Prevention. CDC. 2020. Available from: https://www.cdc.gov/diabetes/basics/type1.html
» https://www.cdc.gov/diabetes/basics/type1.html
Chen Y, Hu Y, Lin M, Jenkins AJ, Keech AC, Mott R, et al. Therapeutic effects of PPARα agonists on diabetic retinopathy in type 1 diabetes models. Diabetes. 2013;62(1):261-72.
Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet. 2010;376(9735):124-36.
ClinicalTrials. National Library of medicine. [cited 2020 July 14]. Available from: Available from: https://clinicaltrials.gov/ct2/show/NCT01320345
» https://clinicaltrials.gov/ct2/show/NCT01320345
Corcóstegui B, Durán S, González-Albarrán MO, Hernández C, Ruiz-Moreno JM, Salvador J, et al. Update on Diagnosis and Treatment of Diabetic Retinopathy: A Consensus Guideline of the Working Group of Ocular Health (Spanish Society of Diabetes and Spanish Vitreous and Retina Society). J Ophthalmol. 2017;2017:8234186.
DiMeglio LA, Evans-Molina C, Oram RA. Type 1 diabetes. Lancet . 2018;391(10138):2449-2462.
Flaxel CJ, Adelman RA, Bailey ST, Fawzi A, Lim JI, Vemulakonda GA, et al. Diabetic Retinopathy Preferred Practice Pattern®. Ophthalmology. 2020;127(1):66-145.
Fox TE, Bewley MC, Unrath KA, Pedersen MM, Anderson RE, Jung DY, et al. Circulating sphingolipid biomarkers in models of type 1 diabetes. J Lipid Res.2011;52(2):509-17.
Holm LJ, Haupt-Jorgensen M, Giacobini JD, Hasselby JP, Bilgin M, Buschard K. Fenofibrate increases very-long-chain sphingol ipids and improves blood glucose homeostasis in NOD mice. Diabetologia. 2019;62(12):2262-72.
International Diabetes Federation. IDF. Diabetes and the Eye. [ cited 2020 July 14]. Available from: Available from: https://idf.org/our-activities/care-prevention/eye-health.html
» https://idf.org/our-activities/care-prevention/eye-health.html
Jia G, Hill MA, Sowers JR. Diabetic Cardiomyopathy: An Update of Mechanisms Contributing to This Clinical Entity. Circ Res. 2018;122(4):624-638.
Keech AC, Mitchell P, Summanen PA, O’Day J, Davis TM, Moffitt MS, et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet . 2007;370(9600):1687- 1697.
Klein R. Retinopathy in a population-based study. Trans Am Ophthalmol Soc. 1992;90:561-594.
Lexicomp. Fenobirate and derivatives. [ citad 2020 August 4]. Available from: Available from: https://online.lexi.com/lco/action/doc/retrieve/docid/multinat_f/4830776?cesid=agVv7anRLuA&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3Dfenofibrate%26t%3Dname%26va%3Dfenofibrate#use
Liu Q, Zhang X, Cheng R, Ma J xing, Yi J, Li J. Salutary effect of fenofibrate on type 1 diabetic retinopathy via inhibiting oxidative stress-mediated Wnt/β-catenin pathway activation. Cell Tissue Res. 2019;376:165-77.
Malur P, Menezes A, DiNicolantonio J, O’Keefe J, Lavie C. The microvascular and macrovascular benefits of fibrates in diabetes and the metabolic syndrome: A review. Mo Med. 2017;114(6):464-471.
Mobasseri M, Shirmohammadi M, Amiri T, Vahed N, Hosseini Fard H, Ghojazadeh M. Prevalence and incidence of type 1 diabetes in the world: a systematic review and meta-analysis. Health Promot Perspect. 2020;10(2):98-115.
Nentwich MM, Ulbig MW. Diabetic retinopathy - ocular complications of diabetes mellitus. World J Diabetes . 2015;6(3):489-99.
Noonan J, Jenkins A, Ma J, Keech A, Wang J, Lamoureux E. An update on the molecular actions of fenofibrate and its clinical effects on diabetic retinopathy and other microvascular end points in patients with diabetes. Diabetes . 2013;62(12):3968-3975. DOI:10.2337/db13-0800
» https://doi.org/10.2337/db13-0800
Pearsall EA, Cheng R, Matsuzaki S, Zhou K, Ding L, Ahn B, et al. Neuroprotective effects of PPARα in retinopathy of type 1 diabetes. PLoS One. 2019;14(2):1-17.
Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation. 1998;98(19):2088-93.
UN News. UN leads bid for cheaper insulin, expanding access for diabetics worldwide [citad 2020 July 14]. Available from: Available from: https://news.un.org/en/story/2019/11/1051241
» https://news.un.org/en/story/2019/11/1051241
Wang J, Song Y, Wang Q, Kralik PM, Epstein PN. Causes and characteristics of diabetic cardiomyopathy. Rev Diabet Stud. 2006;3(3):108-17.
Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes:estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27(5):1047-1053.
World Health Organization. WHO. 2020. Diabetes .[ citad 2020 July 14] . Available from: Available from: https://www.who.int/news-room/fact-sheets/detail/diabetes
» https://www.who.int/news-room/fact-sheets/detail/diabetes
Zhang J, Cheng Y, Gu J, Wang S, Zhou S, Wang Y, et al. Fenofibrate increases cardiac autophagy via FGF21/SIRT1 and prevents fibrosis and inflammation in the hearts of Type 1 diabetic mice. Clin Sci. 2016;130(8):625-41.
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Brazilian Journal of Pharmaceutical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content of the journal, except where identified, is licensed under a Creative Commons attribution-type BY.
The on-line journal has open and free access.
